tiprankstipranks
Advertisement
Advertisement

FHTX Stock Latest News

Foghorn Therapeutics Reports Q2 Results and Pipeline Progress
Company AnnouncementsFoghorn Therapeutics Reports Q2 Results and Pipeline Progress
13d ago
8K
FHTX
Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)
PremiumThe Fly
Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)
13d ago
FHTX
Foghorn Therapeutics Stockholders Approve Directors and Governance Matters
PremiumCompany Announcements
Foghorn Therapeutics Stockholders Approve Directors and Governance Matters
2M ago
8K
FHTX
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
PremiumThe Fly
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
3M ago
FHTX
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline
PremiumCompany Announcements
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline
3M ago
8K
FHTX
Foghorn Therapeutics: AACR 2026 Data De‑Risk Pipeline and Expand Commercial Opportunity, Supporting Buy Rating and $13 Target
PremiumRatingsFoghorn Therapeutics: AACR 2026 Data De‑Risk Pipeline and Expand Commercial Opportunity, Supporting Buy Rating and $13 Target
4M ago
FHTX
Foghorn Therapeutics presents new preclinical data for FHD-909
Premium
The Fly
Foghorn Therapeutics presents new preclinical data for FHD-909
4M ago
FHTX
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
Premium
Company Announcements
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
4M ago
8K
FHTX
Maintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst
PremiumRatings
Maintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst
5M ago
FHTX
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway
PremiumRatings
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway
5M ago
FHTX
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
PremiumCompany Announcements
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
5M ago
8K
FHTX
Reigniting FHD-286: Chromatin-Targeted Synergy in Menin-Resistant AML Underpins Buy Rating on Foghorn
PremiumRatings
Reigniting FHD-286: Chromatin-Targeted Synergy in Menin-Resistant AML Underpins Buy Rating on Foghorn
5M ago
FHTX
Is FHTX a Buy, Before Earnings?
PremiumPre-EarningsIs FHTX a Buy, Before Earnings?
6M ago
FHTX
Foghorn Therapeutics Names Veteran Executive as New CFO
Premium
Company Announcements
Foghorn Therapeutics Names Veteran Executive as New CFO
6M ago
8K
FHTX
Foghorn Therapeutics appoints Maynard as Chief Financial Officer
Premium
The Fly
Foghorn Therapeutics appoints Maynard as Chief Financial Officer
6M ago
FHTX
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
PremiumThe Fly
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
6M ago
FHTX
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
PremiumRatings
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
6M ago
FHTX
Foghorn Therapeutics Announces $50 Million Equity Financing
PremiumCompany Announcements
Foghorn Therapeutics Announces $50 Million Equity Financing
7M ago
8K
FHTX
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
8M ago
FHTX
NUVL
Foghorn Therapeutics initiated with a Buy at BTIG
PremiumThe FlyFoghorn Therapeutics initiated with a Buy at BTIG
8M ago
FHTX
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher
Premium
Company Announcements
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher
9M ago
8K
FHTX
Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
Premium
Ratings
Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
9M ago
FHTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >